ReviewJournal of clinical medicine2023
Microvascular Obstruction in Acute Myocardial Infarction, a Potential Therapeutic Target.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Hemorrhagic Myocardial Infarction and Intramyocardial Hemorrhage: From Microvascular Damage to Emerging Therapeutic Targets.Medical sciences (Basel, Switzerland) · 2026Review
- Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Vessel.Cardiology research · 2026Article
- Myocardial ischemia-reperfusion injury after acute myocardial infarction: spatiotemporal mechanisms and endotype-matched multi-target modulation by compounds from traditional Chinese medicine.Frontiers in cardiovascular medicine · 2026Review
- Effect of intravenous methotrexate carried by lipid nanoemulsion in patients with anterior ST-elevation myocardial infarction.International journal of cardiology. Heart & vasculature · 2025Article
- Early prediction of microvascular obstruction prior to percutaneous coronary intervention.Scientific reports · 2025Article
- Prehospital pulse-dose glucocorticoid on index of microvascular resistance in patients with ST-segment elevation myocardial infarction: a sub-study of the PULSE-MI trial.Journal of inflammation (London, England) · 2025Article
- Epicardial fat volume assessment and strain analysis by cardiac magnetic resonance: a novel method for evaluating microcirculation dysfunction after myocardial infarction.Cardiovascular diagnosis and therapy · 2025Article
- Cardiac Magnetic Resonance Imaging in Diagnostics and Cardiovascular Risk Assessment.Diagnostics (Basel, Switzerland) · 2025Review
- Cardioprotective therapies for ST-elevation myocardial infarction: the emerging role of thyroid hormone: a narrative review.Frontiers in endocrinology · 2025Review
- Impact of early coronary angiography on short-term clinical outcomes in patients with acute myocardial infarction: a retrospective study.American journal of translational research · 2025Article
- Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia/reperfusion through modulating macrophages polarization.Cardiovascular diabetology · 2024Article
- The Use of Thrombectomy during Primary Percutaneous Coronary Intervention: Resurrecting an Old Concept in Contemporary Practice.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Microvascular obstruction (MVO) is a recognised phenomenon following mechanical reperfusion in patients presenting with ST-segment elevation myocardial infarction (STEMI). Invasive and non-invasive modalities to detect and measure the extent of MVO vary in their accuracy, suggesting that this phenomenon may reflect a spectrum of pathophysiological changes at the level of coronary microcirculation. The importance of detecting MVO lies in the observation that its presence adds incremental risk to patients following STEMI treatment. This increased risk is associated with adverse cardiac remodelling seen on cardiac imaging, increased infarct size, and worse patient outcomes. This review provides an outline of the pathophysiology, clinical implications, and prognosis of MVO in STEMI. It describes historic and novel pharmacological and non-pharmacological therapies to address this phenomenon in conjunction with primary PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.